RANI Rani Therapeutics
- 6.625
- -0.055-0.82%
Rani Therapeutics News
BGC, DRS and AMTX Are Among After Hour Movers
Equifax Reports Weak Sales, Joins Synovus Financial And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday. Shares of Equifax Inc. (NYSE:EFX) fell sharply in today's pre-market trading after the company re
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersINVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday's regular session. The market value of their outstanding shares is at $7.4 million. As per the news, the Q4 earnings re
Private Companies in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 54% Last Week
Key Insights Significant control over Rani Therapeutics Holdings by private companies implies that the general public has more power to influence management and governance-related decisions 51% of t
12 Health Care Stocks Moving In Friday's Intraday Session
GainersPaxMedica (NASDAQ:PXMD) stock increased by 110.9% to $0.87 during Friday's regular session. The company's market cap stands at $6.4 million. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% to $29.5. T
Express News | Rani Therapeutics Hldgs Option Alert: Apr 19 $2.5 Calls Sweep (7) Near the Ask: 143 @ $2.5 Vs 765 OI; Earnings 5/8 After Close [Est] Ref=$5.12
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays c
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9
Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs with a Buy and lowers the price target from $21 to $9.
Rani Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Rani Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Buy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market Potential
Express News | HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $12
Rani Therapeutics' RaniPill Poised to Revolutionize Obesity Treatment: A Buy Rating Analysis
Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
Earnings Call Summary | Rani Therapeutics(RANI.US) Q4 2023 Earnings Conference
The following is a summary of the Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript:Financial Performance:Unable to provide key points on Financial Performance due to the lack o
Rani Therapeutics GAAP EPS of -$0.27 Beats by $0.04
Rani Therapeutics Cash Runway Extended Into 2025 >RANI
Rani Therapeutics Cash Runway Extended Into 2025 >RANI
Rani Therapeutics: Development of RaniPill HC to Be Ready for Potential Phase 1 Clinical Trials in 2H >RANI
Rani Therapeutics: Development of RaniPill HC to Be Ready for Potential Phase 1 Clinical Trials in 2H >RANI
Analysis
Price Target
No Data
